Risks and Benefits of Bisphosphonate Therapies

Journal of Cellular Biochemistry

Volumn 117, Issue 1, 2016, Pages 20-28

  Reyes, Carlen ^a   Hitz, Mette ^b   Prieto Alhambra, Daniel ^a,c,d   Abrahamsen, Bo ^e,f  

^a INSTITUT UNIVERSITARI D'INVESTIGACIÓ EN ATENCIÓ PRIMÀRIA JORDI GOL   (Spain)

^b HVIDOVRE HOSPITAL   (Denmark)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f HOLBÆK HOSPITAL   (Denmark)

Author keywords

BONE; OSTEOCLAST; OSTEOPOROSIS

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DISEASE; BONE METASTASIS; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FIBROUS DYSPLASIA; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; NEOPLASM; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PATIENT HARM; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT DURATION; RISK ASSESSMENT;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84957309787     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25266     Document Type: Article

References (50)

1. Abrahamsen B, Eiken P, Brixen K,. 2009. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265 (5): 581-592.
2. Abrahamsen B, Eiken P, Eastell R,. 2010. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: A register-based national cohort analysis. J Clin Endocrinol Metab 95 (12): 5258-5265.
3. Abrahamsen B, Pazianas M, Eiken P, Russell RGG, Eastell R,. 2011. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Min Res 27 (3): 679-686.
4. Abrahamsen B, Osmond C, Cooper C,. 2015. Life expectancy in patients treated for osteoporosis: Observational cohort study using national danish prescription data. J Bone Miner Res. Doi: 10.1002/jbmr.2478. [Epub ahead of print].
5. Briot K, Roux C,. 2015. Glucocorticoid-induced osteoporosis. RMD Open 1: e000014.
6. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, et al., 2010. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28 (22): 3582-3590.
7. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J,. 2014. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25 Suppl 3:iii124-137.
8. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, et al., 2009. National Osteoporosis Guideline Group (NOGG). Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62 (2): 105-108.
9. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK,. 1996. Esophagitis associated with the use of alendronate. N Engl J Med 335 (14): 1016-1021.
10. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al., 2012. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27 (12): 2544-2550.
11. Dwan K, Phillipi CA, Steiner RD, Basel D,. 2014. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane database Syst Rev 7: CD005088.
12. Eriksen EF, Díez-Pérez A, Boonen S,. 2014. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review. Bone 58: 126-135.
13. Etminan M, Lévesque L, Fitzgerald JM, Brophy JM,. 2009. Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: A case-control study. Aliment Pharmacol Ther 29 (11): 1188-1192.
14. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N,. 2009. Effectiveness of bisphosphonate therapy in a community setting. Bone 44 (1): 153-159.
15. Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C,. 2013. Response to comments on: Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: A meta-analysis. Osteoporos Int 24 (6): 1931-1932.
16. Ghirardi A, Scotti L, Vedova GD, D'Oro LC, Lapi F, Cipriani F, et al., 2014. Oral bisphosphonates do not increase the risk of severe upper gastrointestinal complications: A nested case-control study. BMC Gastroenterol 14: 5.
17. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V,. 2010. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 341: c4444.
18. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L,. 2009. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: A self-controlled case-series safety analysis. PLoS ONE 4 (3): e4720.
19. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM,. 2008. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168 (8): 826-831.
20. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al., 2013. Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8 (1-2): 136.
21. Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, et al., 2014. Effect of bisphosphonate use on risk of postmenopausal breast cancer: Results from the randomized clinical trials of alendronate and zoledronic Acid. JAMA Intern Med 174 (10): 1550-1557.
22. Jansen JP, Bergman GJ, Huels J, Olson M,. 2009. Prevention of vertebral fractures in osteoporosis: Mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin 25 (8): 1861-1868.
23. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY,. 2013. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24 (1): 23-57.
24. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al., 2015. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res 30 (1): 3-23.
25. Kim SH, Jeong JB, Kim JW, Koh SJ, Kim BG, Lee KL, et al., 2014. Clinical and endoscopic characteristics of drug-induced esophagitis. World J Gastroenterol 20 (31): 10994-10999.
26. Knopp-Sihota JA, Cummings GG, Homik J, Voaklander D,. 2013. The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: A population-based nested cohort study. BMC Geriatr 13: 36.
27. Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH,. 2010. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res 25 (1): 20-31.
28. Lin D, Kramer JR, Ramsey D, Alsarraj A, Verstovsek G, Rugge M, Parente P, Graham DY, El-Serag HB,. 2013. Oral bisphosphonates and the risk of Barrett's esophagus: Case-control analysis of US veterans. Am J Gastroenterol 108 (10): 1576-1583.
29. Lyles KW, Colõn-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al., 2007. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799-1809.
30. Majumdar SR, Lix LM, Yogendran M, Morin SN, Metge CJ, Leslie WD,. 1998. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008). J Clin Endocrinol Metab 4: 1236-1242.
31. Mendoza N, Sánchez-Borrego R, Villero J, Barõ F, Calaf J, Cancelo MJ, et al., 2013. 2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis. Maturitas 76 (1): 99-107.
32. Naniwa T, Maeda T, Mizoshita T, Hayami Y, Watanabe M, Banno S, Ito R,. 2008. Alendronate-induced esophagitis: Possible pathogenic role of hypersensitivity to alendronate. Intern Med 47 (23): 2083-2085.
33. National Institute for Health and Care Excellence (2008, update 2011) [Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)].[TA160]. London: National Institute for Health and Care Excellence.
34. Oh YH, Yoon C, Park SM,. 2012. Bisphosphonate use and gastrointestinal tract cancer risk: Meta-analysis of observational studies. World J Gastroenterol 18 (40): 5779-5788.
35. Pazianas M, Cooper C, Ebetino FH, Russell RG,. 2010. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 6: 325-343.
36. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RGG,. 2012. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study. Osteoporos Int 23 (11): 2693-2701.
37. Peris P, Torra M, Olivares V, Reyes R, Monegal A, Martínez-Ferrer A, et al., 2011. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49 (4): 706-709.
38. Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C, Arden NK,. 2011. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: Population based retrospective cohort study. BMJ 343: d7222.
39. Reid IR., 2012. Pharmacotherapy of Paget's disease of bone. Expert Opin Pharmacother 13 (5): 637-646.
40. Russell RG, Watts NB, Ebetino FH, Rogers MJ,. 2008. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19 (6): 733-759.
41. Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA,. 2008. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: Population based case-control study. BMJ 336 (7648): 813-816.
42. Schilcher J, Michaëlsson K, Aspenberg P,. 2011. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364 (18): 1728-1737.
43. Schiodt M, Reibel J, Oturai P, Kofod T,. 2014. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: A retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117 (2): 204-213.
44. Shane E, Ebeling PR, Abrahamsen B, Adler a R, Brown TD, Cheung AM, et al., 2014. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res 29 (1): 1-23.
45. Singh S, Singh AG, Murad MH, Limburg PJ,. 2013. Bisphosphonates are associated with reduced risk of colorectal cancer: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. Elsevier Inc 11 (3): 232-239.e1.
46. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N,. 2013. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: Prior work and current challenges. Osteoporos Int 24 (1): 237-244.
47. Van Staa TP, Geusens P, Zhang B, Leufkens HG, Boonen A, Cooper C,. 2007. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford) 46 (3): 460-466.
48. Wysowski DK, Greene P,. 2013. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone 57 (2): 423-428.
49. Ye Y, Mou Y, Bai B, Li L, Chen G-P, Hu S-J,. 2010. Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy. Int J Biochem Cell Biol. Elsevier Ltd. 42 (12): 2056-2064.
50. Zhang Y., 2013. Epidemiology of esophageal cáncer. World J Gastroenterol 19 (34): 5598-5606.